Answers are grounded in this paper and cite their sources.
Collaborative study shows lenalidomide is effective in 73% of children with relapsed LCH, indicating potential for future treatments.
LENDEX is well tolerated and effective in 73% children with relapsed/refractory LCH. Future studies would include nine cycles of LENDEX followed by maintenance for 12 months with 6-mercaptopurine.
No takes yet. Share an insight, caveat, or question.
Uppuluri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: